Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES (ABT)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 05/21 10:00:00 pm
62.115 USD   +0.66%
05/12GLOBAL PREIMPLA : Illumina, Inc., Thermo Fisher Scientific Inc.: 9st..
AQ
05/10Shares of Medical Technology Companies Down After Hours on New St..
DJ
05/10HEART DEVICE PR : Study
DJ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Abbott Laboratories : Abbott Announces Effectiveness of AbbVie Form 10 Registration Statement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2012 | 11:50pm CEST

ABBOTT PARK, Ill., Dec. 7, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the Securities and Exchange Commission (SEC) has declared effective the Form 10 Registration Statement filed by AbbVie Inc., its research-based pharmaceuticals business. Abbott expects to complete the separation of AbbVie on Jan. 1, 2013.

On Nov. 28, 2012, Abbott's board of directors approved the separation of AbbVie, and declared a special dividend distribution of one share of AbbVie common stock for each Abbott common share outstanding as of the close of business on Dec. 12, 2012, the record date for the distribution. Abbott expects the special dividend of AbbVie stock will be distributed on Jan. 1, 2013.

There is no current market for AbbVie common stock. The New York Stock Exchange (NYSE) has authorized the listing of AbbVie common stock under the symbol "ABBV" following the distribution. AbbVie has been advised that trading in its common stock is expected to begin on a "when issued" basis on Dec. 10, 2012, under the symbol "ABBV.WI." "When issued" trading of AbbVie common stock will continue until Abbott pays the special dividend distribution of AbbVie common stock on Jan. 1, 2013. AbbVie "when issued" trades will settle after Jan. 1, 2013, with shares of AbbVie as a standalone company.

Beginning on Dec. 10, 2012, and continuing through Dec. 31, 2012, Abbott expects that common shares of Abbott will trade in two markets on the NYSE: "regular-way" under the symbol "ABT" and in the "ex-distribution" market under the symbol "ABT.WI." Abbott shares trading under "ABT" will carry the right to receive shares of AbbVie through the special dividend distribution. Abbott shares trading under "ABT.WI" will not carry the right to receive shares of AbbVie through the special dividend distribution.

Abbott shareholders who sell their shares in the "regular-way" market before Jan. 1, 2013, will also be selling their entitlement to receive the AbbVie special dividend distribution of AbbVie common stock. Abbott shareholders are encouraged to consult with their financial advisors regarding the specific consequences of selling Abbott common shares on or before Dec. 31, 2012.

On Jan. 2, 2013, regular-way trading will commence on the NYSE for AbbVie under the symbol "ABBV" and will continue for Abbott under the symbol "ABT."

AbbVie will be a research-based specialty biopharmaceuticals company with a broad portfolio of medicines, including leadership in immunology and virology, and a pipeline of breakthrough therapies. Abbott will be one of the largest science-based healthcare companies with diversified market-leading offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals - all aligned with favorable healthcare trends.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.

- Private Securities Litigation Reform Act of 1995 -
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, including the planned separation of the research-based pharmaceutical company from the diversified medical products company and the expected financial results of the two companies after the separation. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2011 and in Item 1A, "Risk Factors," to our quarterly report on Securities and Exchange Commission Form 10-Q for the quarter ended Sept. 30, 2012 and June 30, 2012, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

SOURCE Abbott


© PRNewswire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
05/19ABBOTT LABORATORIES : $30,000 Federal Contract Awarded to Abbott Laboratories
AQ
05/18ABBOTT LABORATORIES PAKISTAN : Dispatch of Final Dividend Warrants of Abbott Lab..
AQ
05/18ABBOTT LABORATORIES : Sen. Duckworth Issues Statement on Confirmation of Scudder..
AQ
05/17ABBOTT LABORATORIES : ' Trademark Application for "COGNISPORT" Filed
AQ
05/17ABBOTT LABORATORIES : ' Trademark Application for "HI-TORQUE BALANCE MIDDLEWEIGH..
AQ
05/17ABBOTT LABORATORIES : Trademark Application for "LIBRE PRO" Filed by Abbott Labo..
AQ
05/15ABBOTT LABORATORIES : Sens. Durbin, Duckworth Issues Statement on 7th Circuit Co..
AQ
05/14ABBOTT LABORATORIES : Sen. Richard J. Durbin (D-IL) News Release
AQ
05/12GLOBAL PREIMPLANTATION GENETIC DIAGN : Illumina, Inc., Thermo Fisher Scientific ..
AQ
05/10Shares of Medical Technology Companies Down After Hours on New Study--Market ..
DJ
More news
News from SeekingAlpha
05/18MeiraGTx Aims For $86 Million U.S. IPO 
05/16THE 30+1 PORTFOLIO : An Average Investor's Reasoning For Buying A Stock 
05/03My Dividend Growth Portfolio - 42 Holdings, 4 Buys 
05/02Reimbursement OK'd in Japan for Abbott's Xience Sierra stent 
04/30Roche Drifting Without Perception-Changing Data